glp-1 agonists oral The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro Oral Small-Molecule GLP-1 Receptor Agonists:
Description
Geriatric Psychiatry

Inoue T, Inoguchi T, Sonoda N, Hendarto H, Makimura H, Sasaki S, Yokomizo H, Fujimura Y, Miura D, Takayanagi R

Several GLP-1RAs CVOTs included patients with chronic kidney disease and showed consistent cardiovascular and some renal benefits

thus, it has the ability to decrease blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin

GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management

Table of Contents: How Does Ozempic Work Compared to Natural GLP1
